OTX2 antibody and other neurodevelopmental markers: stage, compartment and control

Staining a developing or mature nervous system

1. Use a stage-matched positive control, not just a positive tissue. These factors are expressed in defined regions at defined stages. A positive control from the wrong stage is not a control, and it is the commonest reason a developmental stain is reported as failed when the protocol was fine.
2. Treat nuclear factors as low abundance nuclear targets. They need a retrieval and a permeabilisation matched to the nucleus, and frequently an amplified detection. A protocol that works for a cytoskeletal or synaptic marker will report absence for these.
3. Read a synaptic marker as puncta. Presynaptic markers concentrate at terminals, so the readout is puncta number and density along a process rather than total intensity. Total intensity conflates more synapses with more protein per synapse.
4. Know what a neuronal cytoplasmic marker does and does not count. A pan-neuronal cytoplasmic marker fills the cell and is excellent for morphology and for confirming neuronal identity, and it is a poor basis for counting because processes overlap. Count on a nuclear marker and describe with a cytoplasmic one.
5. Fix the fixation and record the interval. Several of these epitopes degrade with time to fixation and behave differently in over-fixed archival blocks. Record fixation time and post-mortem interval with every sample; a cohort inconsistent in these cannot be compared.

Multiplexing across compartments

Combining a nuclear factor, a cytoplasmic neuronal marker and a synaptic marker on one section is straightforward if the primaries come from different hosts, and the compartments themselves help separate the channels visually.

Nervous tissue autofluoresces strongly in the green from lipofuscin and fixation, so put the dimmest marker at a longer wavelength and image an unstained section at the experiment's settings first.

Model systems and their own controls

Organoids and differentiated cultures express these markers on their own schedule, which rarely matches the tissue timetable. Establish the expected pattern in your own system before interpreting a difference between conditions.

Where a differentiation protocol is being assessed, a marker panel read at several time points is far more informative than an endpoint, because the interesting failures are usually in the timing rather than the endpoint.

A gad67 antibody and the isoform that is not gad65

The two glutamate decarboxylases are separate genes with different localisation, so a gad67 antibody has to be specific against GAD65 for an inhibitory neuron claim to mean anything. GAD67 is cytoplasmic and fills somata and processes while the other is vesicle associated, which is how the patterns are told apart. Both are autoantigens, which is a separate clinical use of the same names.

An npy antibody and a small peptide's fixation problem

Neuropeptide Y is a short peptide, so an npy antibody works only if the fixation crosslinks it in place, and a routine protocol written for proteins may wash it out entirely. Perfusion fixation and the vendor's own protocol matter more than the clone. The signal is in dense core vesicles, which gives a punctate pattern in processes rather than a filled soma.

A camkii antibody and the autophosphorylation that matters

CaMKII is activated by calcium and then holds its activity through autophosphorylation at a named threonine, which is why a camkii antibody for total protein is the denominator and the phospho clone is the measurement. The kinase exists as several isoforms and as a large holoenzyme, so the isoform and the expected mass belong in the method.

A cck antibody and a peptide processed from a precursor

Cholecystokinin is cleaved from a precursor into several forms of different length, so a cck antibody has to state which form its epitope covers, and a radioimmunoassay or a mass method is what distinguishes them in a sample. In tissue it marks a neuronal population and shares the small peptide fixation problem, so the protocol is part of the reagent choice.

Common questions

Why is my developmental marker negative?

It may be the wrong stage rather than a failed stain. These factors are expressed in defined regions at defined times, so a stage-matched positive control is what separates absent protein from a protocol problem.

What retrieval do an NKX2.2 antibody and an MECP2 antibody need?

Heat induced retrieval, tested at both a citrate buffer near pH six and a Tris buffer near pH nine on a known positive. The right condition differs between these targets and cannot be assumed from a related one.

How should a synapsin antibody stain be quantified?

As puncta density along a defined length of process or within a defined region, with fixed acquisition settings. Total intensity cannot separate more synapses from more protein per synapse.

Can I count neurons with a UCHL1 antibody or another cytoplasmic pan-neuronal marker?

Poorly, because processes overlap and cell boundaries are unclear. Count on a nuclear neuronal marker and use the cytoplasmic one to describe morphology and confirm identity.

Browse by service class

• Compare Gene synthesis on advertised prices